The 80-minute ‘CEOs Unplugged’ roundtable was introduced by the Association for Accessible Medicines’ interim CEO David Gaugh as – typically – the most anticipated event at the AAM’s two-day annual conference. So it showed, as seats filled quickly and other attendees stood or leaned at the back of the large conference hall in Tampa, eager to hear from the gathered panel of four esteemed US leaders, each boasting decades of experience across a wide range of backgrounds and geographies.
Generics CEOs Unplug At AAM Conference
Four US Leaders Dive Deep On PBMs, Pricing, Biosimilars And Shortages
The AAM’s annual Access! 2024 conference brought its much-enjoyed CEOs Unplugged panel to Tampa again for another engaging discussion on critical issues, challenges and opportunities for generics and biosimilars in the US.
More from Manufacturing Focus
More from In Vivo
• By
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
• By
Three $1bn+ alliances were penned in February, and one exceeded $2bn.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.